Xilio Therapeutics (XLO)
Develops masked immuno-oncology therapies designed to activate within tumors.
Something off on this page? Send us feedback.
Develops masked immuno-oncology therapies intended to concentrate activity in tumors. The model combines internal pipeline development with collaboration-led programs, including XTX101, XTX301, and XTX501; Gilead holds rights to XTX301 under a license agreement.
Builds masked immuno-oncology therapies intended to activate within the tumor microenvironment, aiming to concentrate anti-tumor activity while limiting peripheral effects. The company develops its own pipeline alongside selected collaboration-led programs.
The active portfolio centers on XTX101, XTX301, and XTX501. It discontinued further monotherapy investment in XTX202 when it reprioritized the portfolio.
Under its XTX301 agreement, Gilead holds an exclusive global license to the candidate and related IL-12 molecules. Xilio remains responsible for development through an initial clinical trial, after which Gilead may take on development and commercialization.
The business depends on clinical development, access to financing, and execution of its Gilead collaboration.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $136.0M · Total debt $6.3M · Total assets $154.3M · Shareholders' equity $72.3M
- Revenue
- $18.7M
- Operating income
- −$3.5M
- Net income
- −$6.4M
No dividends on record.
| Institutions | 41.93% | 2.76M shares | |
|---|---|---|---|
| 26 holders · as of Jun 30, 2026 | |||
| Insiders | 0.58% | 37.8K shares | |
| 5 holders · as of Mar 30, 2026 | |||
| Strategic holders | 9.89% | 650.4K shares | |
| 1 holder · as of Dec 19, 2024 | |||
| Other | 47.60% | 3.13M shares | |
| remainder | |||
6.58M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (5.78M in the company's Sep 23, 2026 report, 6.58M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Bain Capital Life Sciences Fund II, L.P.Institution | 10.10% | 664,021 | filed May 15, 2026 |
Bain Capital Life Sciences Investors, LLCInstitution | 10.10% | 664,021 | as of Jun 30, 2026 |
Gilead Sciences, Inc.Strategic10 percent owner | 9.89% | 650,389 | filed Dec 19, 2024 |
Orbimed Advisors LLCInstitution | 9.01% | 592,300 | as of Jun 30, 2026 |
Frazier Life Sciences Management, L.P.Institution | 6.43% | 422,505 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 26, 2026 | James Samuel Shannon | director | +5,000 | $8.79 |
| Feb 13, 2026 | Gilead Sciences, Inc. | 10 percent owner | +3,739,000 | $0.0001 |
| Jan 2, 2026 | Christopher James Frankenfield | officer: Chief Financial Officer | −7,030 | $0.6432 |
| Jan 2, 2026 | Kevin M. Brennan | officer: SVP, FINANCE AND ACCOUNTING | −1,826 | $0.6432 |
- Adagene (ADR)
Masked anti-CTLA-4 program in MSS colorectal cancer
- Agenus
Fc-enhanced CTLA-4/PD-1 combination in MSS colorectal cancer
- Bristol-Myers Squibb
Approved CTLA-4/PD-1 checkpoint regimen across solid tumors
- AstraZeneca (ADR)
CTLA-4 and PD-L1 combination immunotherapy in solid tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Xilio Therapeutics | $9.27 | +2.49% | $59.4M | — | — | 0.9 | +131.1% |
| Adagene (ADR) | $3.00 | −7.12% | $121.6M | — | — | 13.1 | — |
| Agenus | $8.50 | −2.30% | $362.3M | 3.3 | — | 2.7 | +34.3% |
| Bristol-Myers Squibb | $61.76 | −0.79% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| AstraZeneca (ADR) | $164.50 | −2.30% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Median | 13.7 | 12.6 | 3.5 | +6.4% |